DOSAGE RESEARCH
BPC-157 TB-500 dosage, as it appears in the research record
The animal-study doses are real and specific. A validated dose for the assembled blend is not — none exists. This page describes what was administered to which species, never what a person should take.
BPC-157 and TB-500 Dosage Ranges in Preclinical Studies
BPC-157 TB-500 dosage has no validated value for the blend. Commercial research-product labeling commonly pairs the two at fixed combined masses per vial — roughly 10 mg plus 10 mg, or a single 20 mg combined vial — but no peer-reviewed combination dose-finding study exists [11]. Everything below is component-level, expressed as it was administered to animals, and is not human guidance.
The BPC-157 component in rodent models is commonly expressed per body weight, frequently around 10 microg/kg and 10 ng/kg; the transected-Achilles tendon work used 10 microg/kg intraperitoneally [1], and gastric-ulcer cytoprotection has been studied at 400-800 ng/kg in rats. The TB-500 / Thymosin Beta-4 component spans a far wider range: a rat embolic-stroke dose-response study used 2-18 mg/kg intraperitoneally, with the optimal effect modeled near 3.75 mg/kg and 18 mg/kg giving no benefit at all — higher was not better [9]. The mdx muscular-dystrophy study used 150 microg twice weekly for six months [4]. These are species-specific research doses, not a protocol.
Routes Studied in the Component Literature
The 'wolverine injection' commonly discussed online is a parenteral route, but the predominant routes in the underlying efficacy studies are not the ones used in the research community. Subcutaneous and intramuscular administration predominate in community use of the blend, but those are not from controlled human efficacy trials. Intraperitoneal administration predominates in the actual rodent efficacy work for both peptides [1][9]. Intravenous routes appear in the human Phase 1 work on full-length Thymosin Beta-4 and in a BPC-157 IV safety pilot [10]. Local, intra-lesional, and topical routes appear in individual-compound wound and tendon models.
How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both constituents are supplied as lyophilized powders for research handling, reconstituted in bacteriostatic or sterile water and refrigerated [11]. A common community practice is to reconstitute the two peptides separately or in a shared vial. The caveats are practical and unavoidable: in unregulated material, product identity, purity, and the actual BPC-157:TB-500 ratio are not guaranteed, which compounds the existing identity caveat around TB-500 — fragment versus full-length Thymosin Beta-4 [5]. No human-use reconstitution instructions apply to a research chemical, and none are given here.
For where the regulatory line sits on compounded access — and why the unregulated channel matters — see Wolverine legal status and FDA 503A category. For the half-life and reconstitution figures together with the component data, the readouts above summarize the record.